Literature DB >> 9990072

Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis.

B J Longley1, D D Metcalfe, M Tharp, X Wang, L Tyrrell, S Z Lu, D Heitjan, Y Ma.   

Abstract

Human mastocytosis is characterized by increased mast cells. It usually occurs as a sporadic disease that is often transient and limited in children and persistent or progressive in adults. The c-KIT protooncogene encodes KIT, a tyrosine kinase that is the receptor for mast cell growth factor. Because mutated KIT can transform cells, we examined c-KIT in skin lesions of 22 patients with sporadic mastocytosis and 3 patients with familial mastocytosis. All patients with adult sporadic mastocytosis had somatic c-KIT mutations in codon 816 causing substitution of valine for aspartate and spontaneous activation of mast cell growth factor receptor (P = 0.0001). A subset of four pediatric onset cases with clinically unusual disease also had codon 816 activating mutations substituting valine, tyrosine, or phenylalanine for aspartate. Typical pediatric patients lacked 816 mutations, but limited sequencing showed three of six had a novel dominant inactivating mutation substituting lysine for glutamic acid in position 839, the site of a potential salt bridge that is highly conserved in receptor tyrosine kinases. No c-KIT mutations were found in the entire coding region of three patients with familial mastocytosis. We conclude that c-KIT somatic mutations substituting valine in position 816 of KIT are characteristic of sporadic adult mastocytosis and may cause this disease. Similar mutations causing activation of the mast cell growth factor receptor are found in children apparently at risk for extensive or persistent disease. In contrast, typical pediatric mastocytosis patients lack these mutations and may express inactivating c-KIT mutations. Familial mastocytosis, however, may occur in the absence of c-KIT coding mutations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9990072      PMCID: PMC15534          DOI: 10.1073/pnas.96.4.1609

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  Isolation, detection, and amplification of intact mRNA from dermatome strips, epidermal sheets, and sorted epidermal cells.

Authors:  J Longley; T G Ding; C Cuono; F Durden; C Crooks; S Hufeisen; R Eckert; G S Wood
Journal:  J Invest Dermatol       Date:  1991-12       Impact factor: 8.551

2.  Classification and diagnosis of mastocytosis: current status.

Authors:  D D Metcalfe
Journal:  J Invest Dermatol       Date:  1991-03       Impact factor: 8.551

3.  Mutation of the KIT (mast/stem cell growth factor receptor) protooncogene in human piebaldism.

Authors:  L B Giebel; R A Spritz
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

Review 4.  The skin in mastocytosis.

Authors:  N A Soter
Journal:  J Invest Dermatol       Date:  1991-03       Impact factor: 8.551

5.  SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins.

Authors:  C A Koch; D Anderson; M F Moran; C Ellis; T Pawson
Journal:  Science       Date:  1991-05-03       Impact factor: 47.728

6.  Spontaneous malignant transformation of melanocytes explanted from Wf/Wf mice with a Kit kinase-domain mutation.

Authors:  L Larue; N Dougherty; S Porter; B Mintz
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

7.  c-Kit-kinase induces a cascade of protein tyrosine phosphorylation in normal human melanocytes in response to mast cell growth factor and stimulates mitogen-activated protein kinase but is down-regulated in melanomas.

Authors:  Y Funasaka; T Boulton; M Cobb; Y Yarden; B Fan; S D Lyman; D E Williams; D M Anderson; R Zakut; Y Mishima
Journal:  Mol Biol Cell       Date:  1992-02       Impact factor: 4.138

8.  Tinea versicolor: histologic and ultrastructural investigation of pigmentary changes.

Authors:  I Galadari; M el Komy; A Mousa; K Hashimoto; A H Mehregan
Journal:  Int J Dermatol       Date:  1992-04       Impact factor: 2.736

9.  Dominant negative and loss of function mutations of the c-kit (mast/stem cell growth factor receptor) proto-oncogene in human piebaldism.

Authors:  R A Spritz; L B Giebel; S A Holmes
Journal:  Am J Hum Genet       Date:  1992-02       Impact factor: 11.025

10.  Loss of c-kit expression in cultured melanoma cells.

Authors:  N Lassam; S Bickford
Journal:  Oncogene       Date:  1992-01       Impact factor: 9.867

View more
  100 in total

1.  Paediatric mastocytosis.

Authors:  M C Carter; D D Metcalfe
Journal:  Arch Dis Child       Date:  2002-05       Impact factor: 3.791

Review 2.  Mastocytosis and disorders of mast cell proliferation.

Authors:  Joanne K Simpson; Dean D Metcalfe
Journal:  Clin Rev Allergy Immunol       Date:  2002-04       Impact factor: 8.667

3.  Increased angiogenesis in the bone marrow of patients with systemic mastocytosis.

Authors:  Friedrich Wimazal; John-Hendrik Jordan; Wolfgang R Sperr; Andreas Chott; Sana Dabbass; Klaus Lechner; Hans P Horny; Peter Valent
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

4.  One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes.

Authors:  Karl Sotlar; Luis Escribano; Olfert Landt; Stefanie Möhrle; Sonia Herrero; Antonio Torrelo; Ulrich Lass; Hans-Peter Horny; Burkhard Bültmann
Journal:  Am J Pathol       Date:  2003-03       Impact factor: 4.307

5.  ["Smoldering systemic mastocytosis. "Successful therapy with cladribine].

Authors:  V Schleyer; S Meyer; M Landthaler; R-M Szeimies
Journal:  Hautarzt       Date:  2004-07       Impact factor: 0.751

6.  Hematopoietic stem-cell transplantation for advanced systemic mastocytosis.

Authors:  Celalettin Ustun; Andreas Reiter; Bart L Scott; Ryotaro Nakamura; Gandhi Damaj; Sebastian Kreil; Ryan Shanley; William J Hogan; Miguel-Angel Perales; Tsiporah Shore; Herrad Baurmann; Robert Stuart; Bernd Gruhn; Michael Doubek; Jack W Hsu; Eleni Tholouli; Tanja Gromke; Lucy A Godley; Livio Pagano; Andrew Gilman; Eva Maria Wagner; Tor Shwayder; Martin Bornhäuser; Esperanza B Papadopoulos; Alexandra Böhm; Gregory Vercellotti; Maria Teresa Van Lint; Christoph Schmid; Werner Rabitsch; Vinod Pullarkat; Faezeh Legrand; Ibrahim Yakoub-Agha; Wael Saber; John Barrett; Olivier Hermine; Hans Hagglund; Wolfgang R Sperr; Uday Popat; Edwin P Alyea; Steven Devine; H Joachim Deeg; Daniel Weisdorf; Cem Akin; Peter Valent
Journal:  J Clin Oncol       Date:  2014-08-25       Impact factor: 44.544

7.  "Occult" mastocytosis with activating c-kit point mutation evolving into systemic mastocytosis associated with plasma cell myeloma and secondary amyloidosis.

Authors:  K Sotlar; W Saeger; F Stellmacher; J Stahmer; S Jäckle; P Valent; H-P Horny
Journal:  J Clin Pathol       Date:  2006-08       Impact factor: 3.411

8.  Characterization of a novel human mast cell line that responds to stem cell factor and expresses functional FcεRI.

Authors:  Tanya M Laidlaw; John W Steinke; Adrienne M Tiñana; Chunli Feng; Wei Xing; Bing K Lam; Sailaja Paruchuri; Joshua A Boyce; Larry Borish
Journal:  J Allergy Clin Immunol       Date:  2011-02-01       Impact factor: 10.793

9.  International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis.

Authors:  Jason Gotlib; Animesh Pardanani; Cem Akin; Andreas Reiter; Tracy George; Olivier Hermine; Hanneke Kluin-Nelemans; Karin Hartmann; Wolfgang R Sperr; Knut Brockow; Lawrence B Schwartz; Alberto Orfao; Daniel J Deangelo; Michel Arock; Karl Sotlar; Hans-Peter Horny; Dean D Metcalfe; Luis Escribano; Srdan Verstovsek; Ayalew Tefferi; Peter Valent
Journal:  Blood       Date:  2013-01-16       Impact factor: 22.113

10.  FIP1L1-PDGFRalpha imposes eosinophil lineage commitment on hematopoietic stem/progenitor cells.

Authors:  Kentaro Fukushima; Itaru Matsumura; Sachiko Ezoe; Masahiro Tokunaga; Masato Yasumi; Yusuke Satoh; Hirohiko Shibayama; Hirokazu Tanaka; Atsushi Iwama; Yuzuru Kanakura
Journal:  J Biol Chem       Date:  2009-01-14       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.